143 related articles for article (PubMed ID: 22397585)
1. Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants.
Britto R; Araújo L; Barbosa I; Silva L
Gynecol Endocrinol; 2012 Oct; 28(10):767-9. PubMed ID: 22397585
[TBL] [Abstract][Full Text] [Related]
2. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
[TBL] [Abstract][Full Text] [Related]
3. [Lipid profile modifications in post-menopausal women treated with testosterone gel].
Fernández-Carvajal J; Luz-Araujo H; Guerra-Velázquez M; Reyna-Villasmil E; Santos-Bolívar J; Torres-Cepeda D; Mejia-Montilla J; Reyna-Villasmil N
Endocrinol Nutr; 2012 Jan; 59(1):44-9. PubMed ID: 22115702
[TBL] [Abstract][Full Text] [Related]
4. Effects of estrogen therapy on microalbuminuria in healthy post-menopausal women.
Machado RB; Careta MF; Balducci GP; Araújo TS; Bernardes CR
Gynecol Endocrinol; 2008 Dec; 24(12):681-5. PubMed ID: 19172536
[TBL] [Abstract][Full Text] [Related]
5. An open-label study of subdermal implants of estradiol-only versus subdermal implants of estradiol plus nomegestrol acetate: effects on symptom control, lipid profile and tolerability.
Barbosa IC; Coutinho EM; Oladapo L; Noronha CF; Mota RL; Lopes AC; Lopes RC
Gynecol Endocrinol; 2009 Apr; 25(4):269-75. PubMed ID: 19408176
[TBL] [Abstract][Full Text] [Related]
6. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study.
Khatibi A; Agardh CD; Shakir YA; Nerbrand C; Nyberg P; Lidfeldt J; Samsioe G
Climacteric; 2007 Oct; 10(5):386-92. PubMed ID: 17852141
[TBL] [Abstract][Full Text] [Related]
7. Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease.
Joffe HV; Ridker PM; Manson JE; Cook NR; Buring JE; Rexrode KM
Ann Epidemiol; 2006 Feb; 16(2):105-12. PubMed ID: 16216530
[TBL] [Abstract][Full Text] [Related]
8. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
[TBL] [Abstract][Full Text] [Related]
9. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension.
Modena MG; Rossi R; Muia N; Origliani G; Rombolà O; Molinari R
G Ital Cardiol; 1998 Jun; 28(6):636-44. PubMed ID: 9672776
[TBL] [Abstract][Full Text] [Related]
10. Sex hormone levels and risk of cardiovascular events in postmenopausal women.
Rexrode KM; Manson JE; Lee IM; Ridker PM; Sluss PM; Cook NR; Buring JE
Circulation; 2003 Oct; 108(14):1688-93. PubMed ID: 12975257
[TBL] [Abstract][Full Text] [Related]
11. Assessing fatal cardiovascular disease risk with the SCORE (Systematic Coronary Risk Evaluation) scale in post-menopausal women 10 years after different hormone treatment regimens.
Pérez-López FR; Cuadros-López JL; Fernández-Alonso AM; Cuadros-Celorrio AM; Sabatel-López RM; Chedraui P
Gynecol Endocrinol; 2010 Jul; 26(7):533-8. PubMed ID: 19916873
[TBL] [Abstract][Full Text] [Related]
12. Testosterone pellet implants and migraine headaches: a pilot study.
Glaser R; Dimitrakakis C; Trimble N; Martin V
Maturitas; 2012 Apr; 71(4):385-8. PubMed ID: 22310106
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
Hellgren M; Conard J; Norris L; Kluft C
Maturitas; 2009 Mar; 62(3):287-93. PubMed ID: 19268506
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
15. Effects of subdermal implants of estradiol and testosterone on the endometrium of postmenopausal women.
Filho AM; Barbosa IC; Maia H; Genes CC; Coutinho EM
Gynecol Endocrinol; 2007 Sep; 23(9):511-7. PubMed ID: 17943546
[TBL] [Abstract][Full Text] [Related]
16. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
17. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
[TBL] [Abstract][Full Text] [Related]
18. alpha-Tocopherol and beta-carotene serum levels in post-menopausal women treated with transdermal estradiol and oral medroxyprogesterone acetate.
Clemente C; Caruso MG; Berloco P; Buonsante A; Giannandrea B; Di Leo A
Horm Metab Res; 1996 Oct; 28(10):558-61. PubMed ID: 8934216
[TBL] [Abstract][Full Text] [Related]
19. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women.
Bassol S; Carranza-Lira S; Celis-Gonzalez C; Santoyo S; Murillo A; Martinez N; Santos J; Llaca V; de la Loza FR; Zarain J; da Fonseca AM; Camargos AF; Baracat EC; da Sá MF; Bayo J; Adaro L; Gurucharri C; Murga M; Siseles N; Sayegh F; Tempone A; Tempone LM; Tozzini RI; Boccanera R; Naranjo C; Sanchez F; Gomez G; Blanco S; Reyes-Marquez R; Albrecht G; Rios PC
Maturitas; 2005 Mar; 50(3):189-95. PubMed ID: 15734600
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk assessment with oxidised LDL measurement in postmenopausal women receiving intranasal estrogen replacement therapy.
Kurdoglu M; Yildirim M; Kurdoglu Z; Erdem A; Erdem M; Bilgihan A; Goktas B
Gynecol Endocrinol; 2011 Aug; 27(8):551-7. PubMed ID: 20670096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
